As far back as the late nineteenth century, the health science establishment began looking into GABA as a metabolic product deprived from plants and microbes. In the 1950s GABA breaks onto the health science stage, identified as an integral part of nervous system activity, mainly as the primary inhibitory neurotransmitter.
GABA activity is now being harnessed and controlled to help a variety of patients who suffer from a variety of health conditions. Interestingly, it appears that GABA may perform and have application for about 29 million Americans who suffer from type 2 diabetes. As most practitioners are aware, the CDC reports that 29 million suffer from this disease. Emerging clinical literature appears that the careful application and timing of GABA as a dietary supplement has been shown to support the body’s ability to suppress glucagon activity. GABA has been shown to support proper beta cell function, thereby potentially increasing the effectiveness of the body’s insulin response in a hyperglycemic state. The strategic application of GABA as a dietary supplement in a clinical setting to the type 2 diabetic population is showing promise. Finally the supportive application of GABA is a unique way to separate and distinguish oneself from other healthcare providers. The use of GABA should be in strong consideration for those diagnosed with either prediabetes or full-fledged type 2 diabetes. This consideration should be even stronger with patients who apparently are not producing enough endogenous insulin.